[Evaluation of the bioavailability of Polfa phenytoin tablets]. / Ocena dostepnosci biologicznej tabletek phenytoin "Polfa".

Bioavailability of Phenytoin "Polfa" tablets was studied in comparison with Epanutin "Parke-Davis" capsules. It was found that the relative degree of bioavailability of Phenytoin in relation to Epanutin as a standard is 70,7 +/- 6,3% (SD). The cause of worse bioavailability of Phenytoin "Polfa" are differences in pharmaceutical forms of both preparations. The necessity to increase an average dose of Phenytoin "Polfa" tablets is suggested to gain optimal concentration of diphenyl-hydantoin in serum, in therapeutic range.

[Serum diphenylhydantoin in epileptic patients (preliminary report)]. / Oznaczanie poziomu dwufenylohydantoiny (DPH) w surowicy krwi u chorych na padaczke (doniesienie wstepne).

Serum DPH level was determined in previously untreated epileptics who were receiving one dose of 300 mg of DPH daily (Phenytoin--Polfa) during 21 days. The DPH level was determined on the 1st, 10th and 21st days after starting treatment. The obtained results show significant individual differences in absorption of DPH. In 5 patients lower therapeutic range was achieved, in one patient the level was very high and in two cases the therapeutic concentration could not have been achieved. This indicates the necessity of control serum DPH determinations for establishing the individual therapeutic dose of the drug.